Janux Therapeutics opens Phase 1 combo trial of JANX013 and JANX007 in mCRPC
Janux Therapeutics is recruiting for a first-in-human Phase 1 study pairing JANX013 with JANX007 in metastatic castration-resistant prostate cancer.
- Janux Therapeutics is running a first-in-human, Phase 1, open-label, multicenter study of JANX013 combined with JANX007 in adults with metastatic castration-resistant prostate cancer, assessing safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy.1 The study, registered under NCT07813637, is listed as recruiting, with an actual start date and first posted date of September 10, 2026. Enrollment is estimated at 110 participants1, and both drugs are given by IV dosing. Primary completion is estimated for July 2029.
Fact check notes
- Checker's noteThe claim that this was 'one new trial record for the week' is not supported by the clinicaltrials.gov source, which contains no information about weekly posting volume.
- Sentence removed
Janux Therapeutics posted one new trial record for the week, a Phase 1 combination study in prostate cancer.
unsupported: The source document does not mention any weekly posting count or context about being the sole new trial for the week; this appears to be an editorial addition not verifiable from the primary source.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.